Close monitoring and early intervention: management principles for cystic fibrosis in Denmark

IF 2.2 4区 医学 Q4 IMMUNOLOGY
Apmis Pub Date : 2024-01-24 DOI:10.1111/apm.13375
Tavs Qvist, Bibi Uhre Nielsen, Hanne Vebert Olesen, Inger Hee Mabuza Mathiesen, Daniel Faurholt-Jepsen, Terese L. Katzenstein, Jannik Helweg-Larsen, Frederikke Rönsholt, Majbritt Jeppesen, Mette Frahm Olsen, Frederik Fouirnaies Buchvald, Kim Gjerum Nielsen, Søren Jensen-Fangel, Tania Pressler, Marianne Skov
{"title":"Close monitoring and early intervention: management principles for cystic fibrosis in Denmark","authors":"Tavs Qvist,&nbsp;Bibi Uhre Nielsen,&nbsp;Hanne Vebert Olesen,&nbsp;Inger Hee Mabuza Mathiesen,&nbsp;Daniel Faurholt-Jepsen,&nbsp;Terese L. Katzenstein,&nbsp;Jannik Helweg-Larsen,&nbsp;Frederikke Rönsholt,&nbsp;Majbritt Jeppesen,&nbsp;Mette Frahm Olsen,&nbsp;Frederik Fouirnaies Buchvald,&nbsp;Kim Gjerum Nielsen,&nbsp;Søren Jensen-Fangel,&nbsp;Tania Pressler,&nbsp;Marianne Skov","doi":"10.1111/apm.13375","DOIUrl":null,"url":null,"abstract":"<p>Cystic fibrosis (CF) care in Denmark has been characterized by close monitoring and pre-emptive treatment of lung disease and other CF-related complications. Continuous evaluation through data collection and commitment to clinical research has incrementally improved outcomes. This approach has been in line with best practices set forth by European Standards of Care but has also gone beyond Society standards particularly pertaining to early treatment with high-dose combination antimicrobial therapy. Despite a high prevalence of severe CF variants, lung function has been among the best in Europe. In this review, the Danish approach to management of CF prior to the introduction of new CF modulator treatment is explained and benchmarked. Downsides to the Danish approach are discussed and include increased burden of treatment, risk of antimicrobial resistance, side-effects and costs.</p>","PeriodicalId":8167,"journal":{"name":"Apmis","volume":"132 4","pages":"223-235"},"PeriodicalIF":2.2000,"publicationDate":"2024-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/apm.13375","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Apmis","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/apm.13375","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Cystic fibrosis (CF) care in Denmark has been characterized by close monitoring and pre-emptive treatment of lung disease and other CF-related complications. Continuous evaluation through data collection and commitment to clinical research has incrementally improved outcomes. This approach has been in line with best practices set forth by European Standards of Care but has also gone beyond Society standards particularly pertaining to early treatment with high-dose combination antimicrobial therapy. Despite a high prevalence of severe CF variants, lung function has been among the best in Europe. In this review, the Danish approach to management of CF prior to the introduction of new CF modulator treatment is explained and benchmarked. Downsides to the Danish approach are discussed and include increased burden of treatment, risk of antimicrobial resistance, side-effects and costs.

Abstract Image

密切监测和早期干预:丹麦囊性纤维化的管理原则。
在丹麦,囊性纤维化(CF)治疗的特点是对肺部疾病和其他 CF 相关并发症进行密切监测和先期治疗。通过收集数据和致力于临床研究进行持续评估,逐步改善了治疗效果。这种方法符合《欧洲护理标准》规定的最佳实践,但也超越了协会标准,特别是在早期使用大剂量联合抗菌疗法方面。尽管严重 CF 变异的发病率很高,但其肺功能在欧洲一直名列前茅。在这篇综述中,对丹麦在引入新的CF调节剂治疗之前的CF管理方法进行了解释和基准分析。文中讨论了丹麦方法的缺点,包括治疗负担加重、抗菌药耐药性风险、副作用和成本。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Apmis
Apmis 医学-病理学
CiteScore
5.20
自引率
0.00%
发文量
91
审稿时长
2 months
期刊介绍: APMIS, formerly Acta Pathologica, Microbiologica et Immunologica Scandinavica, has been published since 1924 by the Scandinavian Societies for Medical Microbiology and Pathology as a non-profit-making scientific journal.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信